Inflammatory change of fatty liver induced by intraportal low-dose lipopolysaccharide infusion deteriorates pancreatic insulin secretion in fructose-induced insulin-resistant rats

Liver International

Volumn 28, Issue 8, 2008, Pages 1167-1175

  Hsieh, Po Shiuan ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Chronic steatohepatitis; Fatty liver; Fructose fed rats; Portal endotoxaemia

Indexed keywords

C REACTIVE PROTEIN; INSULIN; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIET RESTRICTION; ENDOTOXEMIA; FATTY LIVER; GLUCOSE CLAMP TECHNIQUE; HISTOPATHOLOGY; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NONHUMAN; PANCREAS FUNCTION; PROTEIN DETERMINATION; RAT;

ANIMALS; BLOOD PRESSURE; ENDOTOXINS; FATTY LIVER; FRUCTOSE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HYPERGLYCEMIA; INFUSIONS, PARENTERAL; INSULIN; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; MALE; METABOLIC SYNDROME X; PANCREAS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48949107625     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01714.x     Document Type: Article

References (36)

1. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Med 2005; 22: 1141-5.
2. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998; 114: 842-5.
3. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-62.
4. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-23.
5. Crespo J, Cayon A, Fernandez-GIL P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
6. Bykov I, Junnikkala S, Pekna M, Lindros KO, Meri S. Effect of chronic ethanol consumption on the expression of complement components and acute-phase proteins in liver. Clin Immunol 2007; 124: 213-20.
7. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? [see comment]. Diabetologia 1998; 41: 1241-8.
8. Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: Implications for nonalcoholic fatty liver disease pathophysiology [see comment]. Hepatology 2001; 34(Part 1): 694-706.
9. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis [see comment]. Gut 2001; 48: 206-11.
10. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991; 100: 513-9.
11. Brun P, Castagliuolo I, Leo VD, et al. Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol - Gastrointestinal Liver Physiol 2007; 292: G518-25. l
12. Hayakawa T, Kondo T, Shibata T, et al. Exocrine pancreatic function in chronic liver diseases. Am J Gastroenterol 1991; 86: 201-4.
13. Katakura Y, Yotsuyanagi H, Hashizume K, et al. Pancreatic involvement in chronic viral hepatitis. World J Gastroenterol 2005; 11: 3508-13.
14. Takahashi H, Imamura M, Mikami Y, Yamauchi H. Exacerbation of acute pancreatitis in the presence of chronic liver injury in rats, with special reference to therapeutic efficacy of prostaglandin E1. Pancreas 1999; 19: 199-204.
15. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21: 89-104.
16. Hsieh P-S, Cheng W-T, Liu T-T, Loh C-H, Chang B-C. Diminution of hypertriglyceridemia-induced pressor effect under hyperinsulinemic condition in normal and fructose-induced insulin resistant rats. Chin J Physiol 2007; 50: 99-104.
17. Kerem M, Bedirli A, Pasaoglu H, et al. Role of ghrelin and leptin in predicting the severity of acute pancreatitis. Dig Dis Sci 2007; 52: 950-5.
18. Lee RG. Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler. Hepatology 1995; 21: 1742-3.
19. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome [erratum appears in Hepatology 2003; 38: 536]. Hepatology 2003; 37: 917-23.
20. Fan J-G, Li F, Cai X-B, Peng Y-D, Ao Q-H, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders [see comment]. J Gastroenterol Hepatol 2007; 22: 1086-91.
21. Hanley AJG, Williams K, Festa A, Wagenknecht LE, D'agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes 2005; 54: 3140-7.
22. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004; 27: 1427-32.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man [see comment]. Diabetologia 1985; 28: 412-9.
24. Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance [see comment]. Am J Physiol 1979; 237: E214-23.
25. Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes/Metab Res Rev 2001; 17: 164-74.
26. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IκK-beta and NF-kappaB. Nat Med 2005; 11: 183-90.
27. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108: 218-24.
28. Rivera CA, Tcharmtchi MH, Mendoza L, Smith CW. Endotoxemia and hepatic injury in a rodent model of hindlimb unloading. J Appl Physiol 2003; 95: 1656-63.
29. Rivera CA, Adegboyega P, Van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-9.
30. Muller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45: 805-12.
31. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.
32. Dunger A, Cunningham JM, Delaney CA, et al. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin secretion and cause DNA damage in unweaned-rat islets: Extent of nitric oxide involvement. Diabetes 1996; 45: 183-9.
33. Buschard K, Aaen K, Horn T, Van Damme J, Bendtzen K. Interleukin 6: A functional and structural in vitro modulator of beta-cells from islets of Langerhans. Autoimmunity 1990; 5: 185-94.
34. Ganda O. Secondary Forms of Diabetes. New York: Lea & Febiger, 1994.
35. Abu-Bakare A, Taylor R, Gill GV, Alberti KG. Tropical or malnutrition-related diabetes: A real syndrome? Lancet 1986; 1: 1135-8.
36. Sakai T. Pancreatic exocrine function in patients with chronic liver disease. Kurume Med J 1998; 45: 181-5.